scholarly journals Effect of time interval from diagnosis to treatment for non-small cell lung cancer on survival: a national cohort study in Taiwan

BMJ Open ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. e034351 ◽  
Author(s):  
Chang-Hung Tsai ◽  
Pei-Tseng Kung ◽  
Wei-Yin Kuo ◽  
Wen-Chen Tsai
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Diagnosis ◽  
Cell Lung Cancer ◽  
Treatment Initiation ◽  
Small Cell ◽  
Time Interval ◽  
Newly Diagnosed ◽  
Small Cell Lung ◽  
National Cohort

ObjectivesThis study aimed to determine if treatment delay after non-small cell lung cancer (NSCLC) diagnosis impacts patient survival rate.Study designThis study is a natural experiment in Taiwan. A retrospective cohort investigation was conducted from 2004 to 2010, which included 42 962 patients with newly diagnosed NSCLC.MethodsWe identified 42 962 patients with newly diagnosed NSCLC in the Taiwan Cancer Registry from 2004 to 2010. We calculated the time interval between diagnosis and treatment initiation. All patients were followed from the index date to death or the end of 2012. Cox proportional hazard models were used to examine the relationship between mortality and time interval.ResultsWe included 42 962 patients (15 799 men and 27 163 women) with newly diagnosed NSCLC. The mortality rate exhibited a significantly positive correlation to time interval from cancer diagnosis to treatment initiation. The adjusted HRs ranged from 1.04 to 1.08 in all subgroups time interval more than 7 days compared with the counterpart subgroup of the interval from cancer diagnosis to treatment ≤7 days. The trend was also noted regardless of the patients with lung cancer in stage I, stage II and stage III.ConclusionsThere is a major association between time to treat and mortality of patients with NSCLC, especially in stages I and II. We suggest that efforts should be made to minimise the interval from diagnosis to treatment while further study is ongoing to determine causation.

scholarly journals Predictive value of 3′-deoxy-3′-18F-fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer

2021 ◽  
Vol 9 (7) ◽  
pp. e003079
Author(s):  
Masayuki Sato ◽  
Yukihiro Umeda ◽  
Tetsuya Tsujikawa ◽  
Tetsuya Mori ◽  
Miwa Morikawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Initiation ◽  
Early Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Flt Pet ◽  
Programmed Death ◽  
Programmed Death 1

BackgroundAnti-programmed death-1 (anti-PD-1) therapy has shown clinical success in patients with advanced non-small cell lung cancer (NSCLC). However, it is difficult to evaluate the early response to anti-PD-1 therapy. We determined whether changes in 3′-deoxy-3′-[18F]-fluorothymidine (18F-FLT) PET parameters before and soon after treatment initiation predicted the therapeutic effect of anti-PD-1 antibody.MethodsTwenty-six patients with advanced NSCLC treated with anti-PD-1 antibody were enrolled prospectively and underwent 18F-FLT PET before and at 2 and 6 weeks after treatment initiation. Changes in maximal standardized uptake value (ΔSUVmax), proliferative tumor volume (ΔPTV) and total lesion proliferation (ΔTLP) of the lesions were calculated and evaluated for their associations with the clinical response to therapy.ResultsThe disease control rate was 64%. Patients with non-progressive disease (non-PD) had significantly decreased TLP at 2 weeks, and decreased SUVmax, PTV, and TLP at 6 weeks, compared with those with PD, while three of eight (37.5%) patients who responded had increased TLP from baseline at 2 weeks (ie, pseudoprogression). Among the parameters that changed between baseline and 2 weeks, ΔPTV0-2 and ΔTLP0-2 had the highest accuracy (76.0%) to predict PD. Among the parameters that changed between baseline and 6 weeks, ΔSUVmax0-6, ΔPTV0-6 and ΔTLP0-6 had the highest accuracy (90.9%) to predict PD. ΔTLP0-2 (≥60%, HR 3.41, 95% CI 1.34–8.65, p=0.010) and ΔTLP0-6 (≥50%, HR 31.4, 95% CI 3.55 to 276.7, p=0.0019) were indicators of shorter progression-free survival.ConclusionsChanges in 18F-FLT PET parameters may have value as an early predictive biomarker for the response to anti-PD-1 therapy in patients with NSCLC. However, it should be noted that pseudoprogression was observed in 18F-FLT PET imaging at 2 weeks after treatment initiation.Trial registration numberjRCTs051180147.

P-616 Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer

Lung Cancer ◽  
2005 ◽  
Vol 49 ◽  
pp. S280-S281
Author(s):  
K. Giordano ◽  
A. Jatoi ◽  
A. Adjei ◽  
E. Creagan ◽  
G. Croghan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Organ Dysfunction ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Newly Diagnosed ◽  
Small Cell Lung

scholarly journals Prognostic factors in patients with skeletal-related events at non-small-cell lung cancer diagnosis

2017 ◽  
Vol 7 (5) ◽  
pp. 897-902 ◽  
Author(s):  
Hiroyuki Tominaga ◽  
Takao Setoguchi ◽  
Hirofumi Shimada ◽  
Satoshi Nagano ◽  
Hiromi Sasaki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factors ◽  
Small Cell Lung Cancer ◽  
Cancer Diagnosis ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Diagnosis ◽  
Skeletal Related Events

scholarly journals Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

2019 ◽  
Vol 25 (15) ◽  
pp. 4691-4700 ◽  
Author(s):  
Natasha B. Leighl ◽  
Ray D. Page ◽  
Victoria M. Raymond ◽  
Davey B. Daniel ◽  
Stephen G. Divers ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Utility ◽  
Dna Analysis ◽  
Small Cell ◽  
Newly Diagnosed ◽  
Small Cell Lung ◽  
Cell Free Dna ◽  
Free Dna

scholarly journals Clinical implementation of circulating tumour DNA testing for EGFR T790M for detection of treatment resistance in non-small cell lung cancer

2020 ◽  
pp. jclinpath-2020-206668 ◽  
Author(s):  
Tara Spence ◽  
Sheron Perera ◽  
Jessica Weiss ◽  
Sylvie Grenier ◽  
Laura Ranich ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Blood Test ◽  
Small Cell ◽  
Time Interval ◽  
Test Results ◽  
Small Cell Lung ◽  
Mutational Status ◽  
Circulating Tumour Dna

AimsEpidermal growth factor receptor (EGFR) T790M mutations can be detected in the circulating tumour DNA from plasma of patients with non-small cell lung cancer (NSCLC) to triage patients for osimertinib eligibility and monitor patients longitudinally for development of T790M-mediated resistance.MethodsUsing droplet digital PCR (ddPCR), we examined the EGFR T790M status of 343 sequential patients with NSCLC and correlated mutational status with demographic and clinical features. Where available, serial T790M blood test results were assessed to identify clinical triggers and timing of repeat testing.ResultsOf the 343 patients with liquid biopsy test results, 24% were T790M positive. No clear clinical correlation with a T790M positive test result was identified in this study, although the number of metastatic sites did correlate significantly with the presence of EGFR sensitising mutations (L858R or exon 19 deletion) in patient plasma, as a measure of tumour DNA shedding. Of the 59 serial blood tests from patients that initially tested negative, 14% were positive on sequential testing, at a time interval up to 6 months after an initially negative blood test.ConclusionsThe ddPCR test for EGFR T790M mutations effectively triaged 24% of patients for treatment with osimertinib, avoiding the need for invasive tissue biopsy in these patients. Our findings suggest that initial and repeat ctDNA testing can be used to monitor for acquired EGFR T790M resistance for NSCLC.

Comorbidities and relevant outcomes, commonly associated with cancer, of patients newly diagnosed with advanced non‐small‐cell lung cancer in Sweden

2019 ◽  
Vol 29 (1) ◽  
Author(s):  
Stephan Linden ◽  
Josefine Redig ◽  
Ana Banos Hernaez ◽  
Jonas Nilsson ◽  
Dorthee B. Bartels ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Newly Diagnosed ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document